SCHEMBL7005097

SCHEMBL7005097

Cc1cccc([C@@H](C)N[S@+]([O-])C(C)(C)C)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 1/20 0.40
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
CASR P41180 1/20 0.36
SOS1 Q07889 3/20 0.35
GPR139 Q6DWJ6 2/20 0.34
HDAC1 Q13547 1/20 0.34
ACHE P22303 1/20 0.34
ACP3 P15309 1/20 0.34
AOC3 Q16853 1/20 0.32
EGFR P00533 1/20 0.32
PFKFB3 Q16875 2/20 0.32
EPHX1 P07099 1/20 0.31
KCNA5 P22460 1/20 0.31
KCNH2 Q12809 1/20 0.31
KCNB1 Q14721 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2150941 1.00 MAPKAPK2 (0.40) MAPKAPK2ALDH1A1HPGDCASRSOS1
SCHEMBL16322054 1.00 MAPKAPK2 (0.40) MAPKAPK2ALDH1A1HPGDCASRSOS1
SCHEMBL30238648 1.00 MAPKAPK2 (0.40) MAPKAPK2ALDH1A1HPGDCASRSOS1
SCHEMBL16322073 1.00 MAPKAPK2 (0.40) MAPKAPK2ALDH1A1HPGDCASRSOS1
SCHEMBL14974898 0.85 HDAC4 (0.35) ALDH1A1HPGDHDAC8
SCHEMBL15992174 0.85 HDAC4 (0.35) ALDH1A1HPGDHDAC8
SCHEMBL18595922 0.85 CASR (0.38) MAPKAPK2ALDH1A1HPGDCASRSOS1
SCHEMBL23520549 0.84
SCHEMBL2718174 0.84
SCHEMBL2714838 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3107900-B1 5-BENZYLISOQUINOLEINE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES SERVIER LAB (FR) 2017-11-15 EP disclosed
US-9133140-B2 Cycloalkylamne derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-09-15 US disclosed
WO-2015124877-A1 DERIVATIVES OF 5-BENZYLISOQUINOLINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES LES LABORATOIRES SERVIER (FR) 2015-08-27 WO disclosed
US-20120295943-A9 CYCLOALKYLAMINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-11-22 US disclosed
US-20120122941-A1 CYCLOALKYLAMINE DERIVATIVES MARUMOTO SHINJI (JP) 2012-05-17 US disclosed
WO-2010021351-A1 CYCLOALKYLAMINE DERIVATIVE 第一三共株式会社 (JP) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295943-A9 CYCLOALKYLAMINE DERIVATIVES CASR, CALCR, CALCRL MAPKAPK2 2284/4885ALDH1A1 3143/4885HPGD 3499/4885
US-20120122941-A1 CYCLOALKYLAMINE DERIVATIVES CASR, CALCR, CALCRL MAPKAPK2 2284/4885ALDH1A1 3143/4885HPGD 3499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.